Secondary hemophagocytic lymphohistiocytosis
MONDO:0015542Hemophagocytic lymphohistiocytosis due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.
Also known as: acquired hemophagocytic lymphohistiocytosis, acquired hemophagocytic syndrome, reactive hemophagocytic syndrome
31 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
HPV vaccine shows promise for girls on Immune-Suppressing drugs
⭐️ VACCINE ⭐️ CompletedThis study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare immune disease: drug combo shows promise in small study
Disease control CompletedThis study tested a combination of two drugs—interferon-gamma monoclonal antibody and dexamethasone—in 22 adults with a severe immune condition called refractory secondary HLH. The goal was to see if the treatment helps patients recover and how safe it is. Participants received t…
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug aims to calm dangerous immune storms in Still's and lupus patients
Disease control CompletedThis study tested a drug called emapalumab in 33 children and adults with macrophage activation syndrome (MAS), a life-threatening immune overreaction, linked to Still's disease or lupus. The goal was to see if the drug could safely control the condition and reduce the need for h…
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug shows promise for controlling rare immune disorder
Disease control CompletedThis study tested the drug ITACITINIB in 35 adults with a mild form of a rare immune disease called HLH. The goal was to see if the drug could control the disease by improving symptoms within 15 days. The trial is now complete, and results will show how well the drug works for th…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Small study aims to unlock immune chaos in sepsis patients
Knowledge-focused CompletedThis study looked at 27 adults in intensive care to understand the inflammatory profile of macrophage activation syndrome caused by bacterial sepsis. Researchers measured specific immune markers in blood samples taken over five days. The goal is to gather knowledge that could lea…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Researchers dig into patient histories to uncover clues about macrophage activation syndrome
Knowledge-focused CompletedThis completed study reviewed the medical charts of 32 people with Still's disease who developed a serious complication called macrophage activation syndrome (MAS). The goal was to learn more about their symptoms, how long it took for lab values to return to normal, and what trea…
Sponsor: Swedish Orphan Biovitrum • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Scientists gather clues on mysterious immune defects
Knowledge-focused CompletedThis study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC